BMRN — BioMarin Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $10.85bn
- $14.16bn
- $3.22bn
Brief: Biomarin Pharmaceutical Expects Q3 Will Include Acquired Ipr&D Charges Of About $221 Million
Brief: Biomarin Announces Positive Pivotal Phase 3 Data For Palynziq® (Pegvaliase-Pqpz) In Adolescents With Phenylketonuria At 15th International Congress Of Inborn Errors Of Metabolism
Brief: Elliott Investment Management Raises Share Stake In Phillips 66, Takes in HPE
U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkshire Hathaway, Idexx Laboratories
BioMarin Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary
BioMarin Pharma Q2 revenue beats estimates
Brief: BioMarin Pharmaceutical Announces Appointment Of Ian T. Clark To Board Of Directors
US FDA approves PTC Therapeutics' metabolic disorder drug (updated)
US FDA approves PTC Therapeutics' metabolic disorder drug
Brief: BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN®
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin
Brief: Biomarin To Acquire Inozyme Pharma
BioMarin Pharmaceutical Inc reports results for the quarter ended March 31 - Earnings Summary
BioMarin Pharmaceutical Inc expected to post earnings of 71 cents a share - Earnings Preview
Brief: Biomarin Announces Positive Pivotal Data For Palynziq® (Pegvaliase-Pqpz) In Adolescents With Phenylketonuria
US FDA approves Sanofi's bleeding disorder therapy (updated)
U.S. STOCKS ON THE MOVE-Starbucks, Bristol Myers Squibb, Home Depot